CTC
ASND icon

Central Trust Company’s Ascendis Pharma A/S ASND Stock Holding History

Central Trust Company’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$458 – 1580
2026
Q1 		$458 Hold
2
– – ﹤0.01% 1501
2025
Q4 		$427 Buy
+2
New +$413 ﹤0.01% 1459

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Central Trust Company's ASND Position: Q2 2026 in Review

Central Trust Company sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 2 shares — an estimated $458 sold.

Central Trust Company first reported a position in ASND in Q4 2025 and held it in 2 quarters. The position peaked at $458 in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Central Trust Company reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Central Trust Company sold 2 Ascendis Pharma A/S shares in Q2 2026, an estimated $458.
  • Central Trust Company first reported a position in Ascendis Pharma A/S in Q4 2025 and held it in 2 quarters.
  • Central Trust Company's Ascendis Pharma A/S position peaked at $458 in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.